Challenge
The 2014 Ebola epidemic prompted an urgent need for an approved vaccine to treat or prevent the disease in future outbreaks. Based on Battelle’s extensive experience in vaccine testing and managing highly regulated, complex projects involving high-containment pathogens, we were chosen to evaluate the immunogenicity and efficacy of Ebola vaccine candidates to determine if they were protective.
The Solution
Battelle leveraged experience developing surrogate models of disease to work with multiple partner BSL-4 labs to evaluate the vaccines’ efficacy.
Researchers developed novel assays and readouts including:
- ELISA for serum samples to determine the concentration of antibody binding the desired pathogen
- Pseudovirion neutralization assay to test for neutralizing serum antibody
- Flow-cytometry-based assay that examines the cell activation, cytokines releases and other markers of cell activation to determine if activation of a certain population correlates with effectiveness of vaccine and regimen
Contact us today for a free, no-obligation assessment.
Connect with an expert
opens in a new page
The Outcome
Battelle successfully managed work conducted at multiple sites and across multiple subcontractors including vaccine developers, manufacturing consultants and clinical trial providers. The quality data led to one vaccine being FDA-approved and another under FDA review for approval.
We help deliver life-saving diagnostic and therapeutic solutions for victims of chemical and biological warfare or pandemic diseases.
Explore Therapeutics, Prophylaxis and Diagnostics
opens in a new page
Case Studies
Technology Commercialization and Licensing
With over 90 years of research and development experience, Battelle supports all areas of industry with intellectual property licensing focused on bringing our cross-disciplinary expertise to meet our clients' most difficult challenges.
